Now that open enrollment has ended, what are the health law's next challenges?

News outlets are beginning to focus on the next set of implementation chores, as well as the ways in which the law will impact the health care marketplace.  

The New York Times: What's Next For Health Care
The first open enrollment period for health insurance under the Affordable Care Act has just ended, and consumers, insurers and federal officials now face many immediate chores and challenges that will help determine if the law works as intended. Many questions about the law's potential impact on the health care system remain, and here are some preliminary answers (Pear, 4/2).

The Associated Press: Nonprofit Insurers Struggle In New Marketplaces
A smorgasbord of options and lower prices for consumers were two of the chief selling points for President Barack Obama as he promoted his overhaul of the nation's health insurance industry, predicting Americans would see "competition in ways we haven't seen before." Companies were even started as a way to encourage innovation and competition, namely 23 consumer-run, co-op insurers created with the help of $2 billion in federal loans. But rather than promote competition, the co-ops and smaller nonprofits in some states have languished behind major insurers, attracting in some cases minuscule shares of the market (4/2).

The Fiscal Times: Obamacare Spikes Costs For Employers Who Insure Over 170 Million
The health care benefits provided by large employers for over 170  million Americans may be in jeopardy because of costs related to the Affordable Care Act. Large employers with 10,000 or more employees who provide health care insurance to the majority of Americans including employees, retirees and dependents, will see their total costs over ten years increase from $151 billion to $186 billion, or 5.9 percent more than what they would otherwise be spending. Put another way, the ACA will cost large U.S. employers between $4,800 and $5,900 per employee (Leo, 4/2). 

CQ HealthBeat: Working-Age Military Retirees Could Face Higher Health Costs
Active duty personnel and veterans won't be shifted into the new health law marketplaces or Medicaid, a top Defense Department health official told House appropriators Wednesday. But the official said that some military beneficiaries may face higher out-of-pocket costs in the future (Adams, 4/3).

Meanwhile, the Associated Press reports on this development related to a Supreme Court challenge to the overhaul's birth control mandate  -

The Associated Press: Hobby Lobby 401(k) Invests In Birth Control Makers
The company leading the legal challenge against birth control coverage under the new health care law offers its workers a retirement plan that includes investments in companies making contraceptive and abortion drugs. Hobby Lobby Stores Inc. has a 401(k) plan featuring several mutual funds investing in pharmaceutical firms that produce intrauterine birth control devices, emergency contraceptive pills and drugs used in abortion procedures, according to Labor Department documents and a review of fund portfolios (Hananel, 4/2).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials